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The authors want to alert readers to the following two errors identified in the published version.

At page 4 (column 1, 2nd sentence of last paragraph), the sentence should read as: "Young women (35--44 years) with SLE have a 50-fold increased risk of vascular complications..."

In Table 1, the row under the drug "Anifrolumab" states that the drug is at Phase II for Sjögren's syndrome. This has been stated incorrectly and has been removed. The updated Table 1 is now available below:

###### 

Therapeutic agents targeting components of the type I IFN pathway and in clinical development for IFN-driven diseases

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug           Drug MOA                       Development status   Disease
  -------------- ------------------------------ -------------------- --------------------------------------------------------------------------------------------------
  RSLV132        RNA hydrolysis                 Phase II             Systemic lupus erythematosus Sjögren\'s syndrome

  SM101          Anti--immune complex           Phase II             Systemic lupus erythematosus\
                                                                     Lupus nephritis

  BIIB059        Anti-BDCA2 (pDCs)              Phase II             Systemic lupus erythematosus

  MEDI-7734      Anti-ILT7 (pDCs)               Phase I              Dermatomyositis Polymyositis Systemic sclerosis Sjögren\'s syndrome Systemic lupus erythematosus

  JNJ-55920839   Anti--IFN-α/ω                  Phase I              Systemic lupus erythematosus

  AGS-009        Anti--IFN-α                    Phase I\*            Systemic lupus erythematosus

  IFN-α-kinoid   Anti--IFN-α                    Phase II             Dermatomyositis

  Phase II       Systemic lupus erythematosus                        

  Anifrolumab    Anti-IFNAR1                    Phase II             Lupus nephritis

  Phase III      Systemic lupus erythematosus                        

  Baricitinib†   JAK1/JAK2 inhibitor            Phase II             Systemic lupus erythematosus

  PF-04965842    JAK1 inhibitor                 Phase II             Systemic lupus erythematosus
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Development status unknown.

†European Medicines Agency approved for rheumatoid arthritis.

IFN, interferon; IFNAR1, type I interferon alpha receptor subunit 1; ILT7, immunoglobulin-like transcript 7; JAK, Janus kinase; MOA, mechanism of action; pDCs, plasmacytoid dendritic cell.

In the legend of figure 1, the term 'interferon-stimulating genes' appears. The correct term is 'interferon-stimulated genes'.
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